Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications
详细信息 查看全文
- 作者：Jiamei Liana ; b ; Xu-Feng Huanga ; b ; Nagesh Paib ; Chao Denga ; b ; chao@uow.edu.au" class="auth_mail" title="E-mail the corresponding author
- 关键词：5-HT ; serotonin ; 5-HT1BR ; serotonin 5-HT1B receptor ; 5-HT2AR ; serotonergic 5-HT2A receptor ; 5-HT2CR ; serotonergic 5-HT2C receptor ; 5-HTT ; serotonergic 5-HT transporter ; α-MSH ; alpha-melanocyte-stimulating hormone ; ACC ; acetyl-CoA carboxylase ; ACTH ; adrenocorticotrophin ; AgRP ; agouti-related protein ; AMPK ; AMP-activated protein kinase ; AMPKα ; AMP-activated protein kinase α ; Arc ; arcuate nucleus ; BAT ; brown adipose tissue ; BMI ; body mass index ; CART ; cocaine-and amphetamine-regulated transcript ; C
- 刊名：Pharmacological Research
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：106
- 期：Complete
- 页码：51-63
- 全文大小：2372 K
文摘
- •
Betahistine co-treatment ameliorates olanzapine-induced weight gain through hypothalamic H1R AMPKα, NPY pathways.
- •
Betahistine co-treatment reduces olanzapine-induced dyslipidaemia via AMPKα-SREBP-1-PPARα-dependent pathway in the liver.
- •
Co-treatment with betahistine does not affect the therapeutic efficacy of antipsychotics.